• The new revenue recognition standard - life sciences

    Due to the revenue recognition standards recently issued, life sciences entities may need to make changes. We highlight the key considerations and next steps.

  • Navigating the payer landscape in pharma

    A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.

  • Commercial excellence in pharma 3.0

    The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

  • Worldwide research and development incentive guide

    Research and development (R&D) incentives have grown in number and importance in recent years. Read our latest guide detailing R&D incentive regimes in 34 countries.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

  • Pulse of the industry - medical technology report 2013

    Facing regulatory pressures, resource constraints, and changing health care industry, the medtech industry must redefine innovation to deliver value for payers and patients. Read more.

  • Cash on prescription 2013

    The 14 leading pharma companies have up to US$40 billion tied up unnecessarily in working capital. What strategies can help companies increase efficiency?

  • Life Sciences deal sentiment scorecard

    What lies ahead in the deal space? Our scorecard is based on investor presentations, meetings and conversations around the 2013 J.P. Morgan Healthcare Conference.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:




Contact us

EY-Aidan Meagher

Aidan Meagher
Partner
Head of Life Sciences
International Tax Services
 +353 (1) 221 1139
linkedIn Aidan Meagher Aidan Meagher

 

EY-Adrian Browne

Adrian Browne
Partner
Head of Transaction Advisory Services
Email Adrian Browne
 +44 (0)20 7951 0465

 

 

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY - FutureHealth

On February 27th we hosted the HealthXL Global Gathering in Dublin, an exclusive half day meeting for international thought leaders in healthcare with sessions on CHF, Clinical Trials and COPD. HealthXL brings together providers, insurers, pharma, patients, innovative high growth companies and other key stakeholders to review opportunities for digital health innovation.
Read our Press Release

EY - Deal Outlook 2015 webcast

You're invited – Deal Outlook 2015 webcast

Join us on 11 February for an informative session on current deal drivers, market trends and a 2015 deal outlook for various sectors, including life sciences.

EY Life Sciences: Tax Law video

EY - Global Life Sciences - Tax Law video

EY's Virginie Lefebvre-Dutilleul tells us about how EY's legal credentials can add value to our work with life sciences clients.

Services described in the video cannot be provided by member firms in certain jurisdictions such as the United States.